CN107308020B

CN107308020B - Stable polypeptide composition and application thereof

Info

Publication number: CN107308020B
Application number: CN201710545139.8A
Authority: CN
Inventors: 杨祺; 周翠; 曹春来; 黄有泉; 许文威; 王康钊; 安鹏飞; 黄振彪
Original assignee: Zhuhai United Laboratories Co Ltd
Current assignee: Zhuhai United Laboratories Co Ltd
Priority date: 2017-07-06
Filing date: 2017-07-06
Publication date: 2020-11-27
Anticipated expiration: 2037-07-06
Also published as: CN107308020A

Abstract

The invention discloses a stable polypeptide composition and application thereof. The polypeptide composition consists of sulfhydryl-containing polypeptide, polypeptide which is difficult to dissolve in water, solubilizer, stabilizer, preservative, water and pH value regulator. The invention is a result discovered by the inventor unexpectedly: when the stabilizing agent and the preservative exist simultaneously, the problem that impurities are easily generated in the process of placing the raw material of the mixed aqueous solution of the sulfhydryl-containing polypeptide and the slightly-soluble polypeptide is well solved, and the prepared polypeptide composition has the advantages of good raw material quality, stability to light, long-term placement at room temperature and easiness in preparing subsequent preparations.

Description

Stable polypeptide composition and application thereof

Technical Field

The invention belongs to the technical field of polypeptide raw material preparation, and particularly relates to a stable polypeptide composition and application thereof.

Background

The polypeptide is a bioactive substance formed by condensing two or more amino acids and connecting the two or more amino acids by peptide bonds, is an intermediate product of protein, and has a molecular structure between the amino acids and the protein. In organisms, these active biological polypeptides exist not only in the form of polypeptide molecular structures and native conformations, but also play an important biological role in the organism in the way that native biological activity acts, and play a vital biological role in the growth and development and metabolism of the organism. The active biological polypeptide also plays a unique and important physiological role in the defense and nursing processes of skin natural aging, such as proliferation, cell chemotaxis and migration, repair and regeneration, angiogenesis and reconstruction, pigment formation and removal, protein synthesis and secretion, metabolism and regulation and the like of skin tissue cells. Polypeptides, especially some small molecule active peptides, can essentially improve some problems of skin from the outside to the inside due to the special physiological activity effect of the polypeptides, especially some small molecule active peptides, which are nontoxic and easy to be absorbed by the skin, and are widely applied to cosmetic formulations.

Nonapeptide-1, acetyl hexapeptide-8, acetyl octapeptide-3 and other polypeptides are widely applied to cosmetic formulations. In order to better exert the synergistic effect of the polypeptides, several polypeptides are selected from cosmetic formulations for compounding. The researches of researchers of the invention find that the nonapeptide-1, the acetyl hexapeptide-8 and the acetyl octapeptide-3 are easy to generate impurities in the process of placing raw materials after being mixed with other polypeptides, so that the subsequent preparation formulation is difficult and the use effect of the preparation is influenced. Through analysis, the sulfydryl contained in the peptides such as nonapeptide-1, acetyl hexapeptide-8 and acetyl octapeptide-3 is easy to inactivate when being mixed with other polypeptides, particularly the polypeptides which are difficult to dissolve in water and need to be solubilized by a solubilizer. Therefore, further studies are required in order to obtain a stable polypeptide composition.

Disclosure of Invention

The primary object of the present invention is to overcome the drawbacks and disadvantages of the prior art and to provide a stable polypeptide composition. The polypeptide composition solves the problem that sulfhydryl-containing polypeptide is easy to inactivate during compounding, and the prepared compounded raw material has good quality and stability to light and high temperature, can be placed at room temperature for a long time, and is easy to prepare subsequent preparations.

It is another object of the present invention to provide the use of said stabilized polypeptide composition.

The purpose of the invention is realized by the following technical scheme: a stable polypeptide composition comprises sulfhydryl-containing polypeptide, water-insoluble polypeptide, solubilizer, stabilizer, antiseptic, water and pH regulator.

The stable polypeptide composition preferably comprises the following components in percentage by mass: 0.0005 to 1 percent of sulfhydryl-containing polypeptide, 0.0005 to 0.5 percent of polypeptide which is difficult to dissolve in water, 0.5 to 8 percent of solubilizer, 0.02 to 5 percent of stabilizer, 0.5 to 3 percent of preservative, pH value regulator for regulating the pH value to 4.5 to 6.5 and the balance of water.

The sulfhydryl-containing polypeptide comprises one or at least two of nonapeptide-1, acetyl hexapeptide-8 and acetyl octapeptide-3; preferably one or two of nonapeptide-1, acetyl hexapeptide-8 and acetyl octapeptide-3.

The content of the sulfhydryl-containing polypeptide is preferably 0.01-1%.

The polypeptide difficult to dissolve in water comprises but is not limited to at least one of palmitoylated polypeptide; preferably one or both of palmitoyl tetrapeptide-7 and palmitoyl pentapeptide-4.

The content of the polypeptide which is difficult to dissolve in water is preferably 0.01-0.5%.

The solubilizer comprises but is not limited to one or a mixture of more than two of ionic surfactant and nonionic surfactant; preferably one or two of nonionic surfactants; more preferably one of spitting temperatures; most preferably tween-80.

The content of the solubilizer is preferably 0.5-8%.

The stabilizer includes but is not limited to one or a mixture of two of Butyl Hydroxy Anisole (BHA), 2, 6-di-tert-butyl-4-methylphenol (BHT), methionine, sodium thiosulfate, vitamin C, vitamin E, lipoic acid, carnosine, glutathione, propyl gallate, cysteine, sodium bisulfite and sodium metabisulfite.

The content of the stabilizer is preferably 0.02-5%.

The preservative includes, but is not limited to, one or at least two of caprylyl glycol, phenoxyethanol, caprylyl hydroxamic acid, jasmone, 1, 3-propanediol, glycerol, chlorphenesin, 1, 2-hexanediol, ethylhexylglycerol, plant extracts and fermentation products.

The content of the preservative is preferably 0.5-3%.

The pH value regulator comprises one or more than two of hydrochloric acid, sulfuric acid, acetic acid, sodium acetate, lactic acid, malic acid, citric acid, phosphoric acid, sodium hydroxide, sodium carbonate, sodium bicarbonate, disodium hydrogen phosphate or sodium citrate.

The water is preferably purified water.

The stable polypeptide composition is applied to the preparation of cosmetics or dermatology medicines.

A cosmetic comprises active ingredient and cosmetically acceptable carrier; the active ingredient is the stable polypeptide composition or the stable polypeptide composition and other substances with efficacy on the skin.

The substances having efficacy on the skin include, but are not limited to, moisturizing substances, anti-aging substances, whitening substances, and anti-allergic substances.

The moisturizing substance is preferably one or two of glycerin and hyaluronic acid.

The anti-aging substance is preferably one or at least two of alpha-alkyd, 7 alpha-hydroxy-DHEA and retinol.

The cosmetically acceptable carrier comprises a base material and an auxiliary material.

The matrix raw materials are material raw materials forming a cosmetic matrix and comprise oil raw materials, powder raw materials and solvent raw materials; the specific gravity of the base material in the cosmetic is the largest.

The oil raw material comprises oil, grease and wax.

The oil is preferably at least one of mineral oil, vegetable oil, animal oil, silicone oil and synthetic oil; the mineral oil is further preferably liquid vaseline or paraffin oil; the vegetable oil is preferably avocado oil, soybean oil, macadamia nut oil; the animal oil is further preferably lanolin; the silicone oil is more preferably cyclomethicone.

The lipid is preferably a phytosterol ester.

The wax is preferably one or two of carnauba wax and beeswax.

The auxiliary raw materials are substances which enable the cosmetics to be molded and stable or have color, fragrance and preservative effects, and comprise surfactants, essence or spice, pigment and preservative.

The cosmetically acceptable carrier allows the cosmetic to have different forms.

The form of the cosmetic includes, but is not limited to, the following forms: cream cosmetics, honey cosmetics, powder cosmetics, liquid cosmetics, cream cosmetics, gel cosmetics, and foam cosmetics.

A dermatological agent comprises an active ingredient and a pharmaceutically acceptable carrier; the active ingredient is the stabilized polypeptide composition or the stabilized polypeptide composition is combined with other substances having efficacy on the skin.

The pharmaceutically acceptable carrier endows the dermatological drug with different dosage forms, including an internal dosage form, an injection dosage form and an external dosage form.

The oral preparation comprises tablets, pills, powder, granules, oral liquid and capsules.

The injection preparation comprises powder and injection.

The external preparation comprises paste and spray.

Compared with the prior art, the invention has the following advantages and effects: the invention is the achievement that the inventor of the invention found unexpectedly, when the stabilizer and the preservative exist at the same time, the problem that impurities are easy to generate in the process of placing the raw material of the mixed aqueous solution of the sulfhydryl-containing polypeptide and the slightly soluble polypeptide is well solved, the prepared polypeptide composition has good raw material quality and is stable to light, can be placed at room temperature for a long time, and is easy to prepare subsequent preparations, and the details are as follows:

(1) the polypeptide in the composition provided by the invention has a stable structure, is not easy to inactivate, and can well play a role after being prepared into a final formula;

(2) the composition provided by the invention has good safety and is not easy to cause allergy;

(3) the composition provided by the invention has good quality and is stable to light, and can be placed at room temperature for a long time;

(4) the preparation method of the composition provided by the invention is simple and feasible, and is economic and environment-friendly.

Detailed Description

The present invention will be described in further detail with reference to examples, but the embodiments of the present invention are not limited thereto.

Example 1: preparation of acetyl hexapeptide-8 and palmitoyl pentapeptide-4 composition 1

(1) The formulation is shown in table 1:

TABLE 1

Acetyl hexapeptide-8	10g
		Palmitoyl pentapeptide-4	5g
Lipoic acid	2g
		Methionine	3g
Octylene glycol	10g
		Phenoxyethanol	20g
Tween-80	80g
		Sodium hydroxide	Adjusting pH to 6.5
Purified water	Weight is fixed to 1000g

(2) The preparation process comprises the following steps: 80g of Tween-80 and 500g of purified water are added into a dosing tank, and the mixture is fully and uniformly stirred. Sequentially adding 5g of palmitoyl pentapeptide-4 and 10g of acetyl hexapeptide-8, continuously stirring at the rotating speed of 1000rpm for dissolving, dissolving 2g of lipoic acid and 3g of methionine by using 300g of purified water, adding into a mixing tank, adding 10g of caprylyl glycol and 20g of phenoxyethanol, and fully and uniformly stirring. Finally, slowly dripping 2mol/L sodium hydroxide solution into the formula reaction tank, increasing the stirring speed to 1500rpm, adjusting the pH to 5.5, and then weighing to 1000g by using purified water. Filtering with sterile PES filter membrane, and clarifying and transparent the solution.

Example 2: preparation of acetyl hexapeptide-8 and palmitoyl pentapeptide-4 composition 2

(1) The formulation is shown in table 2:

TABLE 2

(2) The preparation process comprises the following steps: 5g of Tween-80 and 500g of purified water are added into a dosing tank, and the mixture is fully and uniformly stirred. Sequentially adding 0.1g of palmitoyl pentapeptide-4 and 0.5g of acetyl hexapeptide-8, continuously stirring at the rotating speed of 1000rpm for dissolving, dissolving 0.1g of lipoic acid and 0.1g of methionine by using 300g of purified water, adding into a mixing tank, adding 0.5g of octyl glycol and 4.5g of phenoxyethanol, and fully and uniformly stirring. Finally, slowly dripping 2mol/L sodium acetate solution into the formula reaction tank, increasing the stirring speed to 1500rpm, adjusting the pH to 5.5, and then weighing to 1000g by using purified water. Filtering with sterile PES filter membrane, and clarifying and transparent the solution.

Example 3: preparation of acetyl hexapeptide-8 and palmitoyl pentapeptide-4 composition 3

(1) The formulation is shown in table 3:

TABLE 3

Acetyl hexapeptide-8	0.5g
		Palmitoyl pentapeptide-4	0.1g
Carnosine	10g
		Cysteine	40g
Phenoxyethanol	8g
		Glycerol	2g
Tween-80	8g
		Sodium carbonate	Adjusting pH to 6.0
Purified water	Weight is fixed to 1000g

(2) The preparation process comprises the following steps: adding 8g of Tween-80 and 500g of purified water into the batching tank, and fully and uniformly stirring. Sequentially adding 0.1g of palmitoyl pentapeptide-4 and 0.5g of acetyl hexapeptide-8, continuously stirring at the rotating speed of 1000rpm for dissolving, dissolving 10g of carnosine and 40g of cysteine by using 300g of purified water, adding into a mixing tank, adding 2g of glycerol and 8g of phenoxyethanol, and fully and uniformly stirring. Finally, slowly dripping 2mol/L sodium carbonate solution into the formula reaction tank, increasing the stirring speed to 1500rpm, adjusting the pH to 6.0, and then weighing to 1000g by using purified water. Filtering with sterile PES filter membrane, and clarifying the solution.

Example 4: preparation of nonapeptide-1, palmitoyl pentapeptide-4 and palmitoyl tetrapeptide-7 composition 4

(1) The formulation is shown in table 4:

TABLE 4

Nonapeptide-1	0.1g
		Palmitoyl pentapeptide-4	0.1g
Palmitoyl tetrapeptide-7	0.05g
		Vitamin C	1g
Sodium metabisulfite	0.2g
		Octanoyl hydroxypentanoic acid	13.5g
Ethyl hexyl glycerol	1.5g
		Tween-80	20g
Hydrochloric acid	Adjusting pH to 4.5
		Purified water	Weight is fixed to 1000g

(2) The preparation process comprises the following steps: 20g of Tween-80 and 500g of purified water are added into a dosing tank, and the mixture is fully and uniformly stirred. Adding 0.1g nonapeptide-1, 0.1g palmitoyl pentapeptide-4 and 0.05g palmitoyl tetrapeptide-7 in sequence, stirring continuously at the rotating speed of 1000rpm for dissolving, dissolving 1g vitamin C and 0.2g sodium metabisulfite with 300g purified water, adding into a preparation tank, adding 13.5g octanoyl hydroxypentanoic acid and 1.5g ethylhexyl glycerol, and stirring fully and uniformly. Finally, slowly dripping 2mol/L hydrochloric acid solution into the formula reaction tank, increasing the stirring speed to 1500rpm, adjusting the pH to 4.5, and then weighing to 1000g by using purified water. Filtering with sterile PES filter membrane, and clarifying and transparent the solution.

Example 5: preparation of nonapeptide-1, palmitoyl pentapeptide-4 and palmitoyl tetrapeptide-7 composition 5

(1) The formulation is shown in table 5:

TABLE 5

Nonapeptide-1	5g
		Palmitoyl pentapeptide-4	1g
Palmitoyl tetrapeptide-7	0.5g
		Vitamin E	2g
Lipoic acid	10g
		1, 3-propanediol	5g
Xinxian Ketone	5g
		Tween-80	16g
Sodium bicarbonate	Adjusting pH to 5.0
		Purified water	Weight is fixed to 1000g

(2) The preparation process comprises the following steps: 16g of Tween-80 and 500g of purified water are added into a dosing tank, and the mixture is fully and uniformly stirred. Adding 5g of nonapeptide-1, 1g of palmitoyl pentapeptide-4 and 0.5g of palmitoyl tetrapeptide-7 in sequence, continuously stirring at the rotating speed of 1000rpm for dissolving, dissolving 2g of vitamin E and 10g of lipoic acid by using 300g of purified water, adding into a mixing tank, adding 5g of menthone and 5g of 1, 3-propanediol, and fully and uniformly stirring. Finally, slowly dripping 2mol/L sodium bicarbonate solution into the formula reaction tank, increasing the stirring speed to 1500rpm, adjusting the pH to 5.0, and then weighing to 1000g by using purified water. Filtering with sterile PES filter membrane, and clarifying and transparent the solution.

Example 6: preparation of acetyl octapeptide-3 and palmitoyl pentapeptide-4 composition 6

(1) The formulation is shown in table 6:

TABLE 6

Acetyl octaPeptide-3	0.5g
		Palmitoyl pentapeptide-4	0.1g
Carnosine	10g
		Sodium thiosulfate	2g
Chlorophytidine ester	15g
		Tween-80	9g
Malic acid	Adjusting pH to 5.2
		Purified water	Weight is fixed to 1000g

(2) The preparation process comprises the following steps: 9g of Tween-80 and 500g of purified water are added into a dosing tank, and the mixture is fully and uniformly stirred. Adding 0.5g of acetyl octapeptide-3 and 0.1g of palmitoyl pentapeptide-4 in sequence, dissolving by stirring continuously at the rotating speed of 1000rpm, dissolving 10g of carnosine and 2g of sodium thiosulfate by using 300g of purified water, adding into a mixing tank, adding 15g of chlorphenesin, and fully and uniformly stirring. Finally, slowly dripping 2mol/L malic acid solution into the formula reaction tank, increasing the stirring speed to 1500rpm, adjusting the pH to 5.2, and then weighing to 1000g by using purified water. Filtering with sterile PES filter membrane, and clarifying and transparent the solution.

Example 7: preparation of acetyl octapeptide-3 and palmitoyl pentapeptide-4 composition 7

(1) The formulation is shown in table 7:

TABLE 7

Acetyl octapeptide-3	2g
		Palmitoyl pentapeptide-4	0.5g
Propyl gallate	1g
		BHA	1g
1, 2-hexanediol	8g
		Tween-80	12g
NaOH	Adjusting pH to 5.6
		Purified water	Weight is fixed to 1000g

(2) The preparation process comprises the following steps: 12g of Tween-80 and 500g of purified water are added into a dosing tank, and the mixture is fully and uniformly stirred. Sequentially adding 2g of acetyl octapeptide-3 and 0.5g of palmitoyl pentapeptide-4, continuously stirring at the rotating speed of 1000rpm for dissolving, dissolving 1g of BHA and 1g of propyl gallate with 300g of purified water, adding into a dosing tank, adding 8g of 1, 2-hexanediol, and fully and uniformly stirring. Finally, slowly dripping 2mol/L sodium hydroxide solution into the formula reaction tank, increasing the stirring speed to 1500rpm, adjusting the pH to 5.6, and then weighing to 1000g by using purified water. Filtering with sterile PES filter membrane, and clarifying and transparent the solution.

EXAMPLE 8 polypeptide composition quality evaluation test

(1) The polypeptide compositions prepared in examples 1 to 7 were taken to perform accelerated tests to examine the quality of the polypeptide compositions provided by the present invention. The polypeptide compositions obtained from control 1 to control 3 were used as controls. The polypeptide compositions of each control group were prepared as follows:

1) control 1 (without preservatives and stabilizers): the formulation is shown in Table 8

TABLE 8

Acetyl hexapeptide-8	0.5g
		Palmitoyl pentapeptide-4	0.1g
Tween-80	8g
		Sodium carbonate	Adjusting pH to 6.0
Purified water	Weight is fixed to 1000g

Preparation: adding 8g of Tween-80 and 500g of purified water into the batching tank, and fully and uniformly stirring. Sequentially adding 0.1g of palmitoyl pentapeptide-4 and 0.5g of acetyl hexapeptide-8, stirring and dissolving continuously at the rotating speed of 1000rpm, slowly dripping 2mol/L sodium carbonate solution into a formula reaction tank, increasing the stirring speed to 1500rpm, adjusting the pH value to 6.0, and then weighing to 1000g by using purified water. Filtering with sterile PES filter membrane, and clarifying and transparent the solution.

2) Control 2 (without preservative): the formulation is shown in Table 9

TABLE 9

Acetyl hexapeptide-8	0.5g
		Palmitoyl pentapeptide-4	0.1g
Carnosine	10g
		Cysteine	40g
Tween-80	8g
		Sodium carbonate	Adjusting pH to 6.0
Purified water	Weight is fixed to 1000g

Preparation: adding 8g of Tween-80 and 500g of purified water into the batching tank, and fully and uniformly stirring. Sequentially adding 0.1g of palmitoyl pentapeptide-4 and 0.5g of acetyl hexapeptide-8, continuously stirring at the rotating speed of 1000rpm for dissolving, dissolving 10g of carnosine and 40g of cysteine by using 300g of purified water, adding into a mixing tank, and fully and uniformly stirring. Finally, slowly dripping 2mol/L sodium carbonate solution into the formula reaction tank, increasing the stirring speed to 1500rpm, adjusting the pH to 6.0, and then weighing to 1000g by using purified water. Filtering with sterile PES filter membrane, and clarifying and transparent the solution.

3) Control 3 (without stabilizer): the formulation is shown in Table 10

Watch 10

Preparation: adding 8g of Tween-80 and 500g of purified water into the batching tank, and fully and uniformly stirring. Sequentially adding 0.1g of palmitoyl pentapeptide-4 and 0.5g of acetyl hexapeptide-8, stirring continuously at the rotating speed of 1000rpm for dissolving, adding 2g of glycerol and 8g of phenoxyethanol, and stirring fully and uniformly. Finally, slowly dripping 2mol/L sodium carbonate solution into the formula reaction tank, increasing the stirring speed to 1500rpm, adjusting the pH to 6.0, and then weighing to 1000g by using purified water. Filtering with sterile PES filter membrane, and clarifying and transparent the solution.

4) Control group 4 (without preservative): the formulations are shown in Table 11

TABLE 11

Nonapeptide-1	0.1g
		Palmitoyl pentapeptide-4	0.1g
Palmitoyl tetrapeptide-7	0.05g
		Vitamin C	1g
Sodium metabisulfite	0.2g
		Tween-80	20g
Hydrochloric acid	Adjusting pH to 4.5
		Purified water	Weight is fixed to 1000g
Total weight of	1000g

The preparation process comprises the following steps: 20g of Tween 80 and 500g of purified water are added into a dosing tank, and the mixture is fully and uniformly stirred. 0.1g of palmitoyl pentapeptide-4, 0.1g of nonapeptide-1 and 0.05g of palmitoyl tetrapeptide-7 are sequentially added, and after the mixture is continuously stirred and dissolved at the rotating speed of 1000rpm, 1g of vitamin C and 0.2g of sodium metabisulfite are dissolved by 300g of purified water, and the mixture is fully stirred and uniformly mixed. Finally, slowly dripping 2mol/L hydrochloric acid solution into the formula reaction tank, increasing the stirring speed to 1500rpm, adjusting the pH to 4.5, and then weighing to 1000g by using purified water. Filtering with sterile PES filter membrane, and clarifying and transparent the solution.

5) Control 5 (without stabilizer): the formulation is shown in Table 12

TABLE 12

Acetyl octapeptide-3	2g
		Palmitoyl pentapeptide-4	0.5g
1, 2-hexanediol	8g
		Tween-80	12g
NaOH	Adjusting pH to 5.6
		Purified water	Weight is fixed to 1000g

The preparation process comprises the following steps: 12g of Tween-80 and 500g of purified water are added into a dosing tank, and the mixture is fully and uniformly stirred. 0.5g of palmitoyl pentapeptide-4 and 2g of acetyl octapeptide-3 are sequentially added, and after the mixture is continuously stirred and dissolved at the rotating speed of 1000rpm, 8g of 1, 2-hexanediol is added, and the mixture is fully stirred and uniformly stirred. Finally, slowly dripping 2mol/L sodium hydroxide solution into the formula reaction tank, increasing the stirring speed to 1500rpm, adjusting the pH to 5.6, and then weighing to 1000g by using purified water. Filtering with sterile PES filter membrane, and clarifying and transparent the solution.

(2) And (3) accelerated test: the polypeptide compositions obtained in examples 1 to 7 and the polypeptide compositions provided in the respective control groups were respectively subjected to a temperature of 25. + -. 2 ℃, a relative humidity of 60. + -. 10%, a light intensity: the test chamber of 200 + -10 LX was left for 6 months and samples were taken at the end of the 0 th, 1 st, 2 nd, 3 rd and 6 th months to examine the stability stress, and the results are shown in Table 13.

TABLE 13 test results of accelerated test

Note: the content of the polypeptide is the percentage of each polypeptide relative to the standard substance

From the test results in table 13, it can be seen that the polypeptide compositions prepared from the control group 1, the control group 2, the control group 3, the control group 4 and the control group 5 have a turbid phenomenon within 1 month, and the content of the polypeptide component is greatly reduced with the time being longer, wherein the polypeptide component is not detected within 1 month in the control group 1 and the control group 4, and the reduction value is greater than 5%. Therefore, the polypeptide compositions prepared from the control group 1, the control group 2, the control group 3, the control group 4 and the control group 5 have poor quality and are unqualified. The polypeptide compositions prepared in the embodiments 1 to 7 of the invention have more stable quality, the clarity of the solution is good after the polypeptide compositions are placed for 6 months, and the content of the single polypeptide component is not reduced by more than 5%.

In conclusion, the polypeptide compositions prepared in examples 1 to 7 of the present invention are stable to light and moisture and can be stored at room temperature for a long period of time.

Example 9 safety test of polypeptide compositions

(1) Multiple skin irritation test

A subject: 28 healthy common-grade New Zealand rabbits (Guangdong province medical laboratory animal center) are selected and randomly divided into 7 groups, each group comprises 4 rabbits, and the rabbits are respectively half male and female and are marked as a test group 1 to a test group 7.

The test substance: example 1 to example 7 the obtained polypeptide compositions were prepared.

The test method comprises the following steps: before the test, the hairs on both sides of the spine of the animal are cut off, the hair removal range is about 3cm multiplied by 3cm, about 0.5ml of the tested substance is smeared on the skin on the left side of the animal, the smearing area is about 2.5cm multiplied by 2.5cm, the tested substance is smeared once a day and is continuously smeared for 14 days, and the other side of the tested substance is used as a blank control. Shearing hair before each smearing from the next day, removing residual test substance with purified water, and treating the control area. The results were observed after 1 hour. The skin irritation intensity was determined by scoring according to table 1 in skin irritation/corrosivity test of the ministry of health of the people's republic of China's standards for cosmetics hygiene ' 2007 edition, treating the control area and the test area in the same manner, calculating the average integral of each animal per day after the test was completed. The subjects of test groups 1 to 7 correspond to application of the polypeptide compositions prepared in examples 1 to 7, respectively.

And (3) test results: the average daily scores for each animal for each group are shown in table 14. According to the skin irritation/corrosivity test judgment standard of the ministry of health of the people's republic of China's book of cosmetics 2007 edition, the polypeptide compositions prepared in examples 1 to 7 are non-irritant in skin irritation strength for many times.

TABLE 14 average daily integration per animal

(2) Acute eye irritation/Corrosion test

A subject: 21 healthy common-grade New Zealand rabbits were selected and randomly divided into 7 groups of 3 rabbits each with 1 male and 2 female, and labeled as test group 1 to test group 7.

The test method comprises the following steps: eye irritation tests without rinsing, reaction scoring and eye irritation strength grading were carried out according to the acute eye irritation/corrosivity test method of the ministry of health of the people's republic of China's ministry of health, cosmetics Standard, 2007 edition. The right eye conjunctival sac of the subjects in test groups 1 to 7 is coated with the polypeptide composition prepared in examples 1 to 7, respectively.

And (3) test results: the mean of the integrals of the acute eye irritation tests for each group are shown in Table 15. According to the judgment standard of the acute eye irritation/corrosiveness test in 2007 edition of the ministry of health of the people's republic of China, the acute eye irritation tests of the polypeptide compositions prepared in examples 1 to 7 are non-irritant to the irritation strength of eyes of New Zealand rabbits.

TABLE 15 mean integral of acute eye irritation test

(3) Patch test on human skin

Subject: 210 subjects were selected and randomly divided into 7 groups of 30, 6 male and 24 female, labeled as trial 1 through trial 7.

The test method comprises the following steps: selecting a qualified spot tester, coating 0.020ml of a test object in the spot tester by a closed spot test method, externally applying a special adhesive tape to the bent side of the forearm of the test object, removing the test object after 24 hours, observing skin reaction 30min after the spot tester of the test object is removed, and recording the result according to the skin reaction grading standard in 2007 edition of "cosmetic hygiene Specification" of the Ministry of public health of the people's republic of China. Test group 1 to test group 7 subjects were treated with the polypeptide compositions obtained by the preparation of examples 1 to 7, respectively.

And (3) test results: the results of the human skin patch test for each group are shown in Table 16. According to the judgment standard of the skin patch test of human body in 2007 edition of the ministry of health of the people's republic of China, the polypeptide compositions prepared in examples 1 to 7 have no adverse skin reaction on human body.

TABLE 16 test results of human skin patches

Example 10: formula of acetyl hexapeptide-8 and palmitoyl pentapeptide-4 essence (1 kilogram)

(A) The formulations are shown in table 17:

TABLE 17

(B) The preparation process comprises the following steps:

1. preparation of the aqueous phase:

1) most of deionized water, glycerol, EDTA-2Na and carbomer 940 are added into the water phase tank, and a small part of water is reserved.

2) Mixing aloe gel, sodium hyaluronate and butanediol with a beaker, stirring to obtain water phase, and adding into water phase tank.

2. Preparation of oil phase:

adding the chinaroot greenbrier seed oil, the phytosterol ester and the macadamia nut oil into the oil phase tank in sequence, heating to 80 ℃, dissolving completely, and stirring uniformly to obtain an oil phase.

3. Mixing two phases, adjusting pH value and homogenizing:

adding the oil phase into the water phase, mixing, adding triethanolamine, homogenizing and emulsifying for 15 minutes by a dispersion machine to completely disperse the oil phase, and stirring at 1600 rpm. A small sample was taken to measure pH and pH was controlled at 6.0.

4. Adding a polypeptide composition:

adding the polypeptide composition according to the prescription amount, adding the reserved small part of water, filtering with a 0.45-micrometer filter membrane, adding the preservative and the essence, and stirring for 30min to obtain the polypeptide essence.

Example 11: formula (1 kg) of nonapeptide-1, palmitoyl pentapeptide-4 and palmitoyl tetrapeptide-7 essence

(A) The formulation is shown in table 18:

watch 18

(B) The preparation process comprises the following steps:

1. preparation of the aqueous phase:

2. Preparation of oil phase:

3. Mixing two phases, adjusting pH value and homogenizing:

4. Adding a polypeptide composition:

Example 12: formula of acetyl octapeptide-3 and palmitoyl pentapeptide-4 essence (1 kilogram)

(A) The formulations are shown in table 19:

watch 19

(B) The preparation process comprises the following steps:

1. preparation of the aqueous phase:

2. Preparation of oil phase:

3. Mixing two phases, adjusting pH value and homogenizing:

4. Adding a polypeptide composition:

In conclusion, the polypeptide compositions prepared in the embodiments 1 to 7 of the present invention have stable quality and good safety, and are easy to prepare subsequent cosmetic preparations.

The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.

Claims

1. A stabilized polypeptide composition characterized by:

the composite material comprises the following components in percentage by mass: 0.0005 to 1 percent of sulfhydryl-containing polypeptide, 0.0005 to 0.5 percent of polypeptide which is difficult to dissolve in water, 0.5 to 8 percent of solubilizer, 0.02 to 5 percent of stabilizer, 0.5 to 3 percent of preservative, pH value regulator for regulating the pH value to 4.5 to 6.5 and the balance of water;

the sulfhydryl-containing polypeptide is one or at least two of nonapeptide-1, acetyl hexapeptide-8 and acetyl octapeptide-3;

the water-insoluble polypeptide is one or two of palmitoyl tetrapeptide-7 and palmitoyl pentapeptide-4;

the solubilizer is tween-80;

the stabilizer is one or a mixture of more than two of butyl hydroxy anisol, methionine, sodium thiosulfate, vitamin C, vitamin E, lipoic acid, carnosine, propyl gallate, cysteine and sodium metabisulfite;

the antiseptic is one or at least two of caprylyl glycol, phenoxyethanol, caprylyl hydroximic acid, jasminon, 1, 3-propylene glycol, glycerol, chlorphenesin, 1, 2-hexanediol and ethylhexylglycerol.

2. The stabilized polypeptide composition of claim 1, wherein:

the pH value regulator is one or a mixture of more than two of hydrochloric acid, sulfuric acid, acetic acid, sodium acetate, lactic acid, malic acid, citric acid, phosphoric acid, sodium hydroxide, sodium carbonate, sodium bicarbonate, disodium hydrogen phosphate and sodium citrate.

3. Use of the stabilized polypeptide composition of claim 1 or 2 for the preparation of a cosmetic or dermatological medicament.

4. A cosmetic characterized by: consists of active ingredients and a cosmetically acceptable carrier; the active ingredient is the stable polypeptide composition of claim 1 or 2, or the stable polypeptide composition of claim 1 or 2 in combination with other substances having efficacy on skin.

5. The cosmetic according to claim 4, characterized in that:

the substance with efficacy on the skin is a moisturizing substance, an anti-aging substance, a whitening substance or an anti-allergic substance;

the cosmetically acceptable carrier comprises a matrix raw material and an auxiliary raw material;

the matrix raw material is a material for forming a cosmetic matrix;

the auxiliary raw materials are materials which enable the cosmetics to be formed and stable or have color, fragrance and preservative effects.

6. A dermatological agent, characterized by: consists of an active ingredient and a pharmaceutically acceptable carrier; the active ingredient is the stable polypeptide composition of claim 1 or 2, or the stable polypeptide composition of claim 1 or 2 in combination with other substances having efficacy on skin.

7. The dermatological agent of claim 6, wherein:

the pharmaceutically acceptable carrier imparts different dosage forms to the dermatological agent.